TIDMC4XD
C4X Discovery Holdings PLC
25 June 2019
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
C4X Discovery and PhoreMost collaboration to accelerate
Parkinson's Disease drug discovery pipeline
25 June 2019 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, today entered into a
collaboration with PhoreMost, a UK-based biopharmaceutical company
dedicated to drugging 'undruggable' disease targets. The
collaboration, focused initially in Parkinson's Disease, will
combine both company's technology platforms.
The addition of PhoreMost's SITESEEKER(R) screening platform
will bolster the C4XD drug discovery pipeline by validating novel
targets already identified by C4XD's proprietary target
identification platform, Taxonomy3(R), and provide chemical
starting points to launch drug discovery programmes.
Clive Dix, Chief Executive Officer of C4XD, said: "As part of
our strategy to become the world's most productive drug discovery
company, we continually assess cutting edge technologies that add
to our current capabilities in target identification and drug
design. PhoreMost has one such technology with the potential to
both validate targets and provide chemistry starting points for our
molecular design platforms. This partnership complements C4XD's
existing target validation collaborations and enables us to
accelerate our portfolio growth whilst decreasing the timelines in
drug discovery."
SITESEEKER(R)'s phenotypic validation of Taxonomy3(R) derived
novel targets will enable C4XD to progress several Parkinson's
Disease targets to multi-target disease area partnering
arrangements, or in-house drug discovery programmes. C4XD's
proprietary drug discovery Conformetrix technology, which allows
the dynamic 3D shapes of free drug molecules to be precisely
measured from experimental data, can exploit the rich information
produced by SITESEEKER(R) to produce commercially attractive small
molecule drugs. The complementary nature of these technology
platforms provides the potential to extend the collaboration to
additional indications in the future.
While the terms of the agreement are not disclosed, it is
expected that both companies would share any revenues on validated
targets produced by the collaboration.
Parkinson's Disease is a progressive neurological disease with
more than an estimated 10 million people worldwide living with the
disease(1) . The total cost of Parkinson's Disease in the US is
c.$52 billion per year, more than double previous estimates(2)
.
Dr Chris Torrance CEO of PhoreMost, said: "We are thrilled to be
joining forces with C4XD within this neurodegeneration
collaboration, a therapeutic area that has a pressing need for new
and better targets. The opportunity to incorporate genetic insights
gained from C4XD's Taxonomy3(R) data alongside our SITESEEKER(R)
screening platform has great potential to reveal highly relevant
novel drug targets. We are also tremendously excited by the
complementarity of our technologies. C4XD's Conformetrix approach
is ideally suited to use the 3D biological shape information
derived from SITESEEKER(R) targets and convert this into small
molecules starting points that will lead to the next generation of
therapeutics."
Further detail on technology platforms used to accelerate PD
drug discovery pipeline
Taxonomy3(R) is a novel in silico platform technology that
utilises proprietary ground-breaking mathematical algorithms to
analyse complex genetic datasets to identify and characterise novel
drug target candidates. Taxonomy3(R) is able to identify previously
unknown genetic linkages and interactions between genes and
biological pathways in a broad range of diseases. This enables the
discovery of targets that cause disease, rather than those that are
simply associated with its symptoms, and thereby provides the best
starting point for drug discovery, biomarker identification and
patient stratification, and ultimately improving the chances of
clinical success.
SITESEEKER(R) from PhoreMost is based on the Company's core
proprietary protein interference or 'PROTEINi' technology. This
probes the entire proteome in a live cell environment for novel
druggable targets linked to any chosen disease using the massive
3-D shape diversity of natural protein fragment (sub-domain)
libraries. This enables the systematic unmasking of cryptic
druggable sites and directly links them to useful therapeutic
functions.
The Conformetrix patented technology platform allows the dynamic
3D-shapes of free drug molecules to be precisely measured from
experimental data, giving medicinal chemists new and unprecedented
insights into the behaviour and physical properties of drug
molecules. The measurement, analysis and use of dynamic 3D-shapes
is at the heart of the C4X drug discovery engine enabling rapid
progress in developing new and better drugs at a fraction of the
cost compared to best industry practice.
1. Parkinson's Foundation -
https://parkinson.org/Understanding-Parkinsons/Statistics
2.Study commissioned by MJFF, Parkinson's Foundation, Abbvie,
ACADIA Pharmaceuticals, Acord Therapeutics, Adamas Pharmaceuticals,
Biogen, American Parkinson's Disease Association and The Parkinson
Alliance (June 2019) -
https://www.michaeljfox.org/news/study-finds-parkinsons-52-billion-economic-burden-double-previous-estimates
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
PhoreMost Ltd
Dr Chris Torrance, Chief Executive Officer chris.torrance@phoremost.com
PhoreMost Media - Zyme Communications +44 (0)7787 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
Notes to Editors:
About PhoreMost Ltd www.phoremost.com
PhoreMost has developed a next-generation phenotypic screening
platform called SITESEEKER(R) that can discern the best new targets
for future therapy and crucially, how to drug them, which has the
potential to significantly increase the diversity and affordability
of novel therapeutics for cancer and other unmet diseases. Based on
the Company's core proprietary 'Protein Interference' technology,
SITESEEKER(R) systematically unmasks cryptic druggable sites across
the entire human genome and directly links them to useful
therapeutic functions in a live-cell context. Using this platform,
PhoreMost is building a pipeline of novel drug discovery programmes
aimed at addressing a range of unmet diseases.
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive
drug discovery engine by using cutting-edge technologies and
expertise to efficiently deliver best-in-class small-molecule
medicines to clinical partners for the benefit of patients. The
Company's business model focuses on replenishing big pharma
discovery pipelines and driving returns through revenue generating
pre-clinical licensing deals. In 2018, C4XD successfully
out-licensed a pre-clinical programme in addictive disorders to
Indivior in a deal worth up to $294m.
C4XD has a state-of-the-art suite of proprietary technologies
across the drug discovery process and accesses further innovative
capabilities and expertise through its growing network of partners.
The Company is actively advancing its diverse pre-clinical
discovery portfolio which is focused on inflammation,
neurodegeneration and oncology (including immuno-oncology).
Opportunities to maximise value from the portfolio are proactively
driven by C4XD's commercial division. The Company is led by a
highly experienced management team and Board who have delivered
significant
value creation within the healthcare sector.
For additional information please go to:
www.c4xdiscovery.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFZLLLKQFLBBF
(END) Dow Jones Newswires
June 25, 2019 02:01 ET (06:01 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024